Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice
Open accessThe DOI matches its Crossref record; 60 of the 62 references it cites were found in a registry or an index.
Abstract
Hyperglycaemia causes endothelial dysfunction, which is the initial process in the development of diabetic vascular complications. Upon injury, endothelial cells undergo an endothelial-to-mesenchymal transition (EndMT), lose their specific marker, and gain mesenchymal phenotypes. This study investigated the effect of liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, on EndMT inhibition and neointima formation in diabetic mice induced by streptozotocin. The diabetic mice with a wire-induced vascular injury in the right carotid artery were treated with or without liraglutide for four weeks. The degree of neointima formation and re-endothelialisation was evaluated by histological assessments. Endothelial fate tracing revealed that endothelium-derived cells contribute to neointima formation through EndMT in vivo. In the diabetic mouse model, liraglutide attenuated wire injury-induced neointima formation and accelerated re-endothelialisation. In vitro, a high glucose condition (30 mmol/L) triggered morphological changes and mesenchymal marker expression in human umbilical vein endothelial cells (HUVECs), which were attenuated by liraglutide or Activin receptor-like 5 (ALK5) inhibitor SB431542. The inhibition of AMP-activated protein kinase (AMPK) signaling by Compound C diminished the liraglutide-mediated inhibitory effect on EndMT. Collectively, liraglutide was found to attenuate neointima formation in diabetic mice partially through EndMT inhibition, extending the potential therapeutic role of liraglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In streptozotocin-induced diabetic mice, liraglutide treatment for 28 days was found to inhibit high glucose and interleukin (IL)-1β-induced EndMT in endothelial cells and consequently attenuate neointima formation via activation of the AMPK pathway, which was evidenced by a reduction of the expression of mesenchymal markers such as smooth muscle 22α (SM22α), vimentin, and Snail [51].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 4×
“Liraglutide is a long-acting analogue of a glucagon-like peptide 1 (GLP-1) receptor agonist and is used for lowering blood glucose in patients with diabetes [17].”
BackgroundInfluentialDiabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,401
Endothelial dysfunction — A major mediator of diabetic vascular disease
Sena, C. M., Pereira, A. M., & Seiça, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.006 · Cited by 797
Endothelial to Mesenchymal Transition in Cardiovascular Disease
Kovacic, J. C., Dimmeler, S., Harvey, R. P., Finkel, T., Aikawa, E., Krenning, G., & Baker, A. H. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.089 · Cited by 631
Evrard, S. M., Lecce, L., Michelis, K. C., Nomura-Kitabayashi, A., Pandey, G., Purushothaman, K.-R., d’Escamard, V., Li, J. R., Hadri, L., Fujitani, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11853 · Cited by 620
Endothelial-to-mesenchymal transition drives atherosclerosis progression
Chen, P.-Y., Qin, L., Baeyens, N., Li, G., Afolabi, T., Budatha, M., Tellides, G., Schwartz, M. A., & Simons, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82719 · Cited by 588
Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders
Piera-Velazquez, S., Li, Z., & Jimenez, S. A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.001 · Cited by 580
Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications
Tabit, C. E., Chung, W. B., Hamburg, N. M., & Vita, J. A. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9134-4 · Cited by 572
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“Recently, a GLP-1 agonist has been found to attenuate atherosclerotic lesions and endothelial function by inhibiting the inflammation process [18,19].”
BackgroundTGF-β Signaling Mediates Endothelial-to-Mesenchymal Transition (EndMT) During Vein Graft Remodeling
Cooley, B. C., Nevado, J., Mellad, J., Yang, D., St. Hilaire, C., Negro, A., Fang, F., Chen, G., San, H., Walts, A. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006927 · Cited by 392
Kanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y., Ishigaki, Y., Kitada, M., Srivastava, S. P., & Koya, D. (2014) · Diabetes · doi:10.2337/db13-1029 · Cited by 359
Nagata, D., Mogi, M., & Walsh, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300643200 · Cited by 331 · cited 1×
“In addition, AMPK signaling is essential for angiogenesis in response to hypoxic stress [58], which contributes to re-endothelisation [55].”
BackgroundPotential mechanisms promoting restenosis in diabetic patients
Aronson, D., Bloomgarden, Z., & Rayfield, E. J. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00496-3 · Cited by 327
Inflammation-Induced Endothelial-to-Mesenchymal Transition
Rieder, F., Kessler, S. P., West, G. A., Bhilocha, S., de la Motte, C., Sadler, T. M., Gopalan, B., Stylianou, E., & Fiocchi, C. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.042 · Cited by 322
Kokudo, T., Suzuki, Y., Yoshimatsu, Y., Yamazaki, T., Watabe, T., & Miyazono, K. (2008) · Journal of Cell Science · doi:10.1242/jcs.028282 · Cited by 321
Sorrentino, S. A., Bahlmann, F. H., Besler, C., Müller, M., Schulz, S., Kirchhoff, N., Doerries, C., Horváth, T., Limbourg, A., Limbourg, F., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.684381 · Cited by 318
Medici, D., Potenta, S., & Kalluri, R. (2011) · Biochemical Journal · doi:10.1042/bj20101500 · Cited by 316
Origin and differentiation of vascular smooth muscle cells
Wang, G., Jacquet, L., Karamariti, E., & Xu, Q. (2015) · The Journal of Physiology · doi:10.1113/jp270033 · Cited by 299
Moonen, J.-R. A. J., Lee, E. S., Schmidt, M., Maleszewska, M., Koerts, J. A., Brouwer, L. A., van Kooten, T. G., van Luyn, M. J. A., Zeebregts, C. J., Krenning, G., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv175 · Cited by 245
Hopper, R. K., Moonen, J.-R. A. J., Diebold, I., Cao, A., Rhodes, C. J., Tojais, N. F., Hennigs, J. K., Gu, M., Wang, L., & Rabinovitch, M. (2016) · Circulation · doi:10.1161/circulationaha.115.020617 · Cited by 242
Mahler, G. J., Farrar, E. J., & Butcher, J. T. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300504 · Cited by 236
Maleszewska, M., Moonen, J.-R. A. J., Huijkman, N., van de Sluis, B., Krenning, G., & Harmsen, M. C. (2013) · Immunobiology · doi:10.1016/j.imbio.2012.05.026 · Cited by 220
Mima, A., Hiraoka-Yamomoto, J., Li, Q., Kitada, M., Li, C., Geraldes, P., Matsumoto, M., Mizutani, K., Park, K., Cahill, C., et al. (2012) · Diabetes · doi:10.2337/db11-1824 · Cited by 203
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186
Cheang, W. S., Tian, X. Y., Wong, W. T., Lau, C. W., Lee, S. S.-T., Chen, Z. Y., Yao, X., Wang, N., & Huang, Y. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301938 · Cited by 181
Wang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., et al. (2013) · Diabetes · doi:10.2337/db12-1025 · Cited by 179
Liu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179 · cited 1×
“Recently, a GLP-1 agonist has been found to attenuate atherosclerotic lesions and endothelial function by inhibiting the inflammation process [18,19].”
BackgroundHyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes
Funk, S. D., Yurdagul, A., & Orr, A. W. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/569654 · Cited by 176
Essential Role of TGF-β Signaling in Glucose-Induced Cell Hypertrophy
Wu, L., & Derynck, R. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.05.010 · Cited by 167
Xu, L., Chen, Y.-G., & Massagué, J. (2000) · Nature Cell Biology · doi:10.1038/35019649 · Cited by 166
Lim, J., Oh, M., Kim, W., Sohn, H., & Park, S. I. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22824 · Cited by 165
Mechanisms of Endothelial to Mesenchymal Transition in the Retina in Diabetes
Cao, Y., Feng, B., Chen, S., Chu, Y., & Chakrabarti, S. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15167 · Cited by 143
Self-citationMicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT
Srivastava, S. P., Koya, D., & Kanasaki, K. (2013) · BioMed Research International · doi:10.1155/2013/125469 · Cited by 133
miR-200b Mediates Endothelial-to-Mesenchymal Transition in Diabetic Cardiomyopathy
Feng, B., Cao, Y., Chen, S., Chu, X., Chu, Y., & Chakrabarti, S. (2015) · Diabetes · doi:10.2337/db15-1033 · Cited by 132
Self-citationLoader, J., Montero, D., Lorenzen, C. H., Watts, R., Méziat, C., Reboul, C., Stewart, S., & Walther, G. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305530 · Cited by 110
Yajima, N., Takahashi, M., Morimoto, H., Shiba, Y., Takahashi, Y., Masumoto, J., Ise, H., Sagara, J., Nakayama, J., Taniguchi, S., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.746453 · Cited by 104
Liu, L., Liu, X., Ren, X., Tian, Y., Chen, Z., Xu, X., Du, Y., Jiang, C., Fang, Y., Liu, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep21602 · Cited by 104
Self-citationPeng, H., Li, Y., Wang, C., Zhang, J., Chen, Y., Chen, W., Cao, J., Wang, Y., Hu, Z., & Lou, T. (2016) · Scientific Reports · doi:10.1038/srep20304 · Cited by 102
Self-citationLi, F. Y. L., Lam, K. S. L., Tse, H., Chen, C., Wang, Y., Vanhoutte, P. M., & Xu, A. (2012) · Circulation · doi:10.1161/circulationaha.112.108159 · Cited by 86
High glucose induced endothelial to mesenchymal transition in human umbilical vein endothelial cell
Yu, C.-H., Suriguga, S., Gong, M., Liu, W., Cui, N.-X., Wang, Y., Du, X., & Yi, Z.-C. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.03.007 · Cited by 76
Tsai, T.-N., Kirton, J. P., Campagnolo, P., Zhang, L., Xiao, Q., Zhang, Z., Wang, W., Hu, Y., & Xu, Q. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.021 · Cited by 72
Self-citationLiu, X., Mujahid, H., Rong, B., Lu, Q., Zhang, W., Li, P., Li, N., Liang, E., Wang, Q., Tang, D., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13360 · Cited by 71
Noels, H., Zhou, B., Tilstam, P. V., Theelen, W., Li, X., Pawig, L., Schmitz, C., Akhtar, S., Simsekyilmaz, S., Shagdarsuren, E., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302878 · Cited by 68
Upregulation of Interleukin-33 in obstructive renal injury
Chen, W., Chang, Y., Su, C., Tsai, T., Chen, S., Hsing, C., & Yang, J. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.010 · Cited by 60
Self-citationHirata, Y., Kurobe, H., Nishio, C., Tanaka, K., Fukuda, D., Uematsu, E., Nishimoto, S., Soeki, T., Harada, N., Sakaue, H., et al. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.057 · Cited by 58
Zhao, J., Miyamoto, S., You, Y.-H., & Sharma, K. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00234.2014 · Cited by 52
High glucose mediates endothelial-to-chondrocyte transition in human aortic endothelial cells
Tang, R., Gao, M., Wu, M., Liu, H., Zhang, X., & Liu, B. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-113 · Cited by 52
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
Lim, S., Lee, G. Y., Park, H. S., Lee, D.-H., Tae Jung, O., Kyoung Min, K., Kim, Y.-B., Jun, H.-S., Hak Chul, J., & Park, K. S. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvw213 · Cited by 47
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Bisgaard, L. S., Bosteen, M. H., Fink, L. N., Sørensen, C. M., Rosendahl, A., Mogensen, C. K., Rasmussen, S. E., Rolin, B., Nielsen, L. B., & Pedersen, T. X. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168396 · Cited by 47
Ke, J., Liu, Y., Yang, J., Lu, R., Tian, Q., Hou, W., Wang, G., Wei, R., & Hong, T. (2017) · Scientific Reports · doi:10.1038/srep41085 · Cited by 38
Yan, F., Zhang, G.-H., Feng, M. H., Zhang, W., Zhang, J., Dong, W., Zhang, C., Zhang, Y., Chen, L., & Zhang, M.-X. (2015) · Molecular Medicine · doi:10.2119/molmed.2014.00259 · Cited by 37
Li, N., Zhao, Y., Yue, Y., Chen, L., Yao, Z., & Niu, W. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.095 · Cited by 37
Percutaneous coronary interventions with drug eluting stents for diabetic patients
Seabra-Gomes, R. (2006) · Heart · doi:10.1136/hrt.2005.062992 · Cited by 28
Eriksson, L., Saxelin, R., Röhl, S., Roy, J., Caidahl, K., Nyström, T., Hedin, U., & Razuvaev, A. (2015) · Journal of Vascular Research · doi:10.1159/000381097 · Cited by 27
Interleukin-1β mediates high glucose induced phenotypic transition in human aortic endothelial cells
Zhu, D., Tang, R., Lv, L., Wen, Y., Liu, H., Zhang, X., Ma, K., & Liu, B. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0358-9 · Cited by 23
Stone, J. D., Holt, A. W., Vuncannon, J. R., Brault, J. J., & Tulis, D. A. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00846.2014 · Cited by 22
Chen, Y., Yang, Q., Zhan, Y., Ke, J., Lv, P., & HUANG, J. C. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.05.055 · Cited by 18
Mader, J. K., Jensen, L., Ingwersen, S. H., Christiansen, E., Heller, S. R., & Pieber, T. R. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0413-4 · Cited by 14
Feng, L., Wang, J., & Ma, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.039 · Cited by 7
Cited by
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
Yang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage
Choi, K. J., Nam, J.-K., Kim, J.-H., Choi, S., & Lee, Y. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0439-4 · Cited by 120
Metadata
- Authors
- Tsai, T.-H., Lee, C.-H., Cheng, C.-I., Fang, Y.-N., Chung, S.-Y., Chen, S.-M., Lin, C.-J., Wu, C.-J., Hang, C.-L., & Chen, W.-Y.
- Affiliations
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Corresponding author
- Chen, Wei-Yu
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-06-14
- Volume
- 8
- Issue
- 6
- Pages
- 589
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC6628350
- OpenAlex
- W2950515961
- Cited by
- 37
- References
- 62
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 9 · 2020: 3 · 2019: 1
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Chang Gung Medical Foundation (CMRPG8E1151, CMRPG8F0351, CMRPG8B0601, CMRPG8D0231-3, CMRPG8E0661-3, CMRPG8F1831, CMRPG8F1681, CMRPG8G1371, CMRPG8G1541)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- liraglutide, endothelial-to-mesenchymal transition, neointima formation, diabetic vascular complications, hyperglycemia, endothelial dysfunction, re-endothelialization, carotid artery, streptozotocin-induced diabetes, GLP-1 receptor agonists, ALK5 inhibition, SB431542, AMPK signaling, human umbilical vein endothelial cells
- MeSH terms
- Liraglutide, Snail Family Transcription Factors, Adenylate Kinase, Animals, Arteries, Diabetes Mellitus, Experimental, Endothelium, Glucose, Humans, Mesoderm, Mice, Inbred C57BL, Mice, Transgenic, RNA, Messenger, Streptozocin, Signal Transduction, Biomarkers, Smad2 Protein, Glucagon-Like Peptide 1, Interleukin-1beta, Neointima, Human Umbilical Vein Endothelial Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.